Terns Pharmaceuticals(US:TERN)2022-03-11 18:33Financial Status and Intellectual Property - The company's cash balance was approximately $166 million as of December 31, 2021, providing a runway into 2024[6, 9] - The company's IP estate includes patents and patent applications potentially extending into the 2040s[6] - The company anticipates 5-year NCE exclusivity (plus 30 month stay) after approval, in addition to patents[121] Pipeline Programs and Milestones - TERN-201 (VAP-1 Inhibitor) AVIATION Part 1 top-line data is expected in March 2022, and Part 2 top-line data in 2H 2022[8, 14, 113] - TERN-501 (THR-β Agonist) Phase 2a trial is starting in 1H 2022, with top-line data expected in 2H 2023[8] - TERN-601 (Oral GLP-1R Agonist) is engaging in IND-enabling activities, with Phase 1 trial initiation planned for 2023[8, 14, 109] - A combination NASH Phase 2a trial of TERN-101 and TERN-501 is planned to start in 1H 2022[14, 45, 48] TERN-501 (THR-β Agonist) - TERN-501 achieved significant dose-dependent changes in PD markers, including a 166% change in SHBG and a -21% change in LDL-c at the 10 mg dose[31, 32, 34] - TERN-501 exhibits superior selectivity for THR-β over THR-α, with a selectivity ratio of 23, compared to 15 for Resmetirom and 2 for VK2809A[13, 25] TERN-201 (VAP-1 Inhibitor) - TERN-201 is a highly selective inhibitor of VAP-1, with minimal potential to inhibit MAO-A or MAO-B[8, 13, 58, 65] - TERN-201 demonstrated complete inhibition of soluble VAP-1 activity in plasma with all single and multiple doses[68, 70, 71]